Movatterモバイル変換


[0]ホーム

URL:


SG11201902886SA - Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors - Google Patents

Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors

Info

Publication number
SG11201902886SA
SG11201902886SASG11201902886SASG11201902886SASG11201902886SASG 11201902886S ASG11201902886S ASG 11201902886SASG 11201902886S ASG11201902886S ASG 11201902886SASG 11201902886S ASG11201902886S ASG 11201902886SASG 11201902886S ASG11201902886S ASG 11201902886SA
Authority
SG
Singapore
Prior art keywords
international
spring house
tyrosine
rule
mckean
Prior art date
Application number
SG11201902886SA
Inventor
Mark Macielag
Raymond Patch
Rui Zhang
Martin A Case
Mark Wall
Yue-Mei Zhang
Original Assignee
Janssen Pharmaceutica Nv
Mark Macielag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=62020814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201902886S(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv, Mark MacielagfiledCriticalJanssen Pharmaceutica Nv
Publication of SG11201902886SApublicationCriticalpatent/SG11201902886SA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) omit n OH iolo 0111M111 001100 011 (10) International Publication Number WO 2018/081367 Al WIPO I PCT (51) International Patent Classification: A61K 38/12 (2006.01) CO7K 14/575 (2006.01) A61K 38/22 (2006.01) C07K 14/46 (2006.01) A61K 38/17 (2006.01) (21) International Application Number: PCT/US2017/058451 (22) International Filing Date: 26 October 2017 (26.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/413,586 27 October 2016 (27.10.2016) US 62/413,613 27 October 2016 (27.10.2016) US (71) Applicant: JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventor; and (71) Applicant: MACIELAG, Mark [US/US]; 1400 McKean Road, Spring House, PA 19477 (US). (72) Inventors: MACIELAG, Mark; 1400 McKean Road, Spring House, PA 19477 (US). PATCH, Raymond, J.; 1400 McKean Road, Spring House, PA 19477 (US). ZHANG, Rui; 1400 McKean Road, Spring House, PA 19477 (US). CASE, Martin A.; 3210 Merryfield Row, San Diego, CA 92121 (US). WALL, Mark; 1400 McKean Road, Spring House, PA 19477 (US). ZHANG, Yue-Mei; 1400 McKean Road, Spring House, PA 19477 (US). (74) Agent: BARANIAK, Andrew, P. et al.; Panitch Schwarze Belisario & Nadel LLP, Two Commerce Square, 2001 Mar- ket Street, Suite 2800, Philadelphia, PA 19103 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS 1-1 Z4PEZIPZ9EZ11ASPEELNRYYZ22Z231-RZ26YLT) I-IN 0 (CH 2 )„-BRIDGE (CH 2 ) r , [V 31 ]gTRZ34Z35Y - N H2 11 1 00 O (57) : The present invention comprises compounds of Formula I wherein: Z4, Z 7 , Zg, Z11, Z22, Z23, Z26, Z30, Z34, Z3 5 , p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. el The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the 0 metabolic syndrome, insulin resistance, and dyslipidemia, among others.
SG11201902886SA2016-10-272017-10-26Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptorsSG11201902886SA (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US201662413613P2016-10-272016-10-27
US201662413586P2016-10-272016-10-27
PCT/US2017/058451WO2018081367A1 (en)2016-10-272017-10-26Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors

Publications (1)

Publication NumberPublication Date
SG11201902886SAtrue SG11201902886SA (en)2019-05-30

Family

ID=62020814

Family Applications (4)

Application NumberTitlePriority DateFiling Date
SG10202107777XASG10202107777XA (en)2016-10-272017-10-26Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
SG11201902873RASG11201902873RA (en)2016-10-272017-10-26Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
SG11201902886SASG11201902886SA (en)2016-10-272017-10-26Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
SG11201902879SASG11201902879SA (en)2016-10-272017-10-26Immunoglobulins and uses thereof

Family Applications Before (2)

Application NumberTitlePriority DateFiling Date
SG10202107777XASG10202107777XA (en)2016-10-272017-10-26Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
SG11201902873RASG11201902873RA (en)2016-10-272017-10-26Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
SG11201902879SASG11201902879SA (en)2016-10-272017-10-26Immunoglobulins and uses thereof

Country Status (39)

CountryLink
US (15)US10961293B2 (en)
EP (5)EP3532486B8 (en)
JP (6)JP7231539B2 (en)
KR (6)KR102653376B1 (en)
CN (4)CN110099692B (en)
AU (6)AU2017348180B2 (en)
BR (3)BR112019008500A2 (en)
CA (3)CA3041674A1 (en)
CL (3)CL2019001110A1 (en)
CO (3)CO2019003938A2 (en)
CR (3)CR20190208A (en)
CY (1)CY1124732T1 (en)
DK (1)DK3532486T3 (en)
DO (3)DOP2019000106A (en)
EC (3)ECSP19029995A (en)
ES (2)ES3025907T3 (en)
HR (1)HRP20211626T1 (en)
HU (1)HUE056442T2 (en)
IL (6)IL266204B2 (en)
JO (3)JOP20190097A1 (en)
LT (1)LT3532486T (en)
MA (3)MA46665B1 (en)
MD (1)MD3532486T2 (en)
MX (6)MX2019004954A (en)
MY (1)MY199666A (en)
NI (2)NI201900043A (en)
PE (3)PE20190917A1 (en)
PH (3)PH12019500723A1 (en)
PL (1)PL3532486T3 (en)
PT (1)PT3532486T (en)
RS (1)RS62677B1 (en)
SA (3)SA519401647B1 (en)
SG (4)SG10202107777XA (en)
SI (1)SI3532486T1 (en)
SM (1)SMT202100647T1 (en)
TW (4)TWI794189B (en)
UY (3)UY37457A (en)
WO (3)WO2018081370A1 (en)
ZA (1)ZA202200648B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP3546474B1 (en)2013-12-182021-07-07President and Fellows of Harvard CollegeCrp capture/detection of gram positive bacteria
JOP20190097A1 (en)*2016-10-272019-04-28Janssen Pharmaceutica NvImmunoglobulins and uses thereof
TWI847981B (en)*2018-04-252024-07-11比利時商健生藥品公司Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
US11780900B2 (en)2018-04-252023-10-10Janssen Sciences Ireland Unlimited CompanyGlucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
WO2020188510A2 (en)*2019-03-192020-09-24Enzene Biosciences LimitedProcess of preparation of glucagon-like peptide-1 (glp-1) receptor agonists and their analogs
WO2020262590A1 (en)*2019-06-282020-12-30味の素株式会社Cyclic peptide production method
AU2020384729A1 (en)2019-11-112022-04-14Boehringer Ingelheim International GmbhNPY2 receptor agonists
CN111494606B (en)*2020-04-242021-12-14广州医科大学New application of neuropeptide Y
CN116171282A (en)2020-08-072023-05-26勃林格殷格翰国际有限公司 Soluble NPY2 receptor agonist
CN115073556A (en)*2021-03-122022-09-20上海天慈生命科学发展有限公司Opioid/neuropeptide FF receptor multi-target cyclic peptide molecule and preparation and application thereof
CN118076367A (en)*2021-06-142024-05-24达比克斯有限责任公司GLP-1 receptor agonists with improved pharmacological and drug delivery properties
WO2023097363A1 (en)*2021-11-302023-06-08Garvan Institute Of Medical ResearchImproved binding proteins and uses thereof
CN115028551B (en)*2022-07-152024-01-05成都普康生物科技有限公司Preparation method of azide-nine glycol-propionic acid
CN116098987A (en)*2023-02-092023-05-12华东医院 Use of galanin in the preparation of medicines for treating non-alcoholic fatty liver disease

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
FR2434149A1 (en)1978-06-221980-03-21Parcor NEW L-CYSTEIN DERIVATIVES
US5393669A (en)*1993-02-051995-02-28Martek Biosciences Corp.Compositions and methods for protein structural determinations
US7166575B2 (en)2002-12-172007-01-23Nastech Pharmaceutical Company Inc.Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2005077094A2 (en)2004-02-112005-08-25Amylin Pharmaceuticals, Inc.Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1718671A2 (en)2004-02-232006-11-08Rheoscience A/SPeptide yy analogues
WO2005089789A2 (en)*2004-03-172005-09-297Tm Pharma A/SY2 selective receptor agonists for therapeutic interventions
MX2007002856A (en)2004-09-022007-09-25Genentech IncHeteromultimeric molecules.
TWI544076B (en)2005-03-312016-08-01Chugai Pharmaceutical Co Ltd A method of manufacturing a polypeptide that controls assembly
DE102005028778A1 (en)2005-06-222006-12-28SUNJÜT Deutschland GmbHMulti-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food
WO2007100535A2 (en)2006-02-222007-09-07Merck & Co., Inc.Oxyntomodulin derivatives
US20090186817A1 (en)*2006-03-212009-07-23Amylin Pharmaceuticals, Inc.Peptide-peptidase inhibitor conjugates and methods of using same
WO2007147901A1 (en)2006-06-222007-12-27Novo Nordisk A/SProduction of bispecific antibodies
KR20090074787A (en)2006-10-052009-07-07센토코 오르토 바이오테크 인코포레이티드 CrC2 antagonist for the treatment of fibrosis
JP2008169195A (en)*2007-01-052008-07-24Hanmi Pharmaceutical Co Ltd Insulin secretory peptide drug conjugates using carrier substances
EP2527369A3 (en)*2007-09-132012-12-19University Of Zurich Prorektorat ForschungMonoclonal amyloid beta (abeta)-specific antibody and uses thereof
JP2011507519A (en)2007-12-192011-03-10セントコア・オーソ・バイオテツク・インコーポレーテツド Design and generation of human de novo pIX phage display library via fusion to pIX or pVII, vectors, antibodies, and methods
EP2362881B1 (en)2008-11-042019-03-13Janssen Pharmaceutica NVCrhr2 peptide agonists and uses thereof
MX2011004427A (en)*2008-11-052011-05-31Hoffmann La RocheNeuropeptide-2-receptor (y-2r) agonists and uses thereof.
JP2012525149A (en)2009-04-272012-10-22オンコメッド ファーマシューティカルズ インコーポレイテッド Method for making heteromultimeric molecules
CN102574903B (en)2009-07-132015-07-08西兰制药公司Acylated glucagon analogues
WO2011033068A1 (en)2009-09-182011-03-24Novo Nordisk A/SLong-acting y2 receptor agonists
KR20120092611A (en)2009-09-302012-08-21글락소 그룹 리미티드Drug fusions and conjugates with extended half life
SMT202400377T1 (en)2010-04-202025-01-14Genmab As FC-CONTAINING PROTEINS OF HETERODIMERIC ANTIBODIES AND METHODS FOR THEIR PRODUCTION
CA2812389C (en)*2010-09-272019-12-31John KehoeAntibodies binding human collagen ii
US8906649B2 (en)2010-09-272014-12-09Janssen Biotech, Inc.Antibodies binding human collagen II
DK2635607T3 (en)2010-11-052019-11-18Zymeworks Inc STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN
KR20190090055A (en)*2011-01-282019-07-31사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR086969A1 (en)2011-06-172014-02-05Hanmi Science Co Ltd CONJUGATE UNDERSTANDING OXONTOMODULIN AND A FRAGMENT OF IMMUNOGLOBULIN, AND ITS USE
RU2675319C2 (en)2011-11-042018-12-18Займворкс Инк.STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN Fc DOMAIN
SI2869848T1 (en)2012-07-042017-01-31F. Hoffmann-La Roche AgCovalently linked antigen-antibody conjugates
SG11201503370WA (en)2012-11-062015-05-28Hanmi Pharm Ind Co LtdLiquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
SG11201504920SA (en)2012-12-272015-07-30Sanofi SaAnti-lamp1 antibodies and antibody drug conjugates, and uses thereof
CN105073781A (en)2013-01-112015-11-18加州生物医学研究所 bovine fusion antibody
SG11201508469YA (en)2013-05-022015-11-27Glaxosmithkline Ip Dev LtdTherapeutic peptides
DK3129406T3 (en)*2014-04-112019-04-01Medimmune Llc CONJUGATED COMPOUNDS INCLUDING CYSTEIN MODIFIED ANTIBODIES
AR100978A1 (en)2014-06-262016-11-16Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
MD20170020A2 (en)2014-07-302017-07-31Ngm Biopharmaceuticals, Inc.Compositions and methods of use for treating metabolic disorders
JP2018534933A (en)*2015-11-022018-11-29ヤンセン ファーマシューティカ エヌ.ベー. Anti-IL1RAP antibody, bispecific antigen-binding molecule that binds IL1RAP and CD3, and use thereof
JOP20190097A1 (en)*2016-10-272019-04-28Janssen Pharmaceutica NvImmunoglobulins and uses thereof
TWI847981B (en)*2018-04-252024-07-11比利時商健生藥品公司Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof

Also Published As

Publication numberPublication date
MA46665A (en)2019-09-04
TW201829455A (en)2018-08-16
ECSP19029942A (en)2019-05-31
KR102704251B1 (en)2024-09-06
KR20190073492A (en)2019-06-26
AU2017348172A1 (en)2019-04-18
WO2018081367A1 (en)2018-05-03
BR112019008417A2 (en)2019-09-03
AU2021269420B2 (en)2023-11-23
KR102573684B1 (en)2023-09-04
KR102653381B1 (en)2024-04-02
PT3532486T (en)2021-11-19
JP7090077B2 (en)2022-06-23
US11732019B2 (en)2023-08-22
US20180125998A1 (en)2018-05-10
AU2021269420A1 (en)2021-12-16
AU2017348180B2 (en)2024-12-12
CA3041672A1 (en)2018-05-03
WO2018081375A1 (en)2018-05-03
MX2024001845A (en)2024-03-06
SMT202100647T1 (en)2022-01-10
JP2020510606A (en)2020-04-09
ES3025907T3 (en)2025-06-10
TW201827456A (en)2018-08-01
IL266206A (en)2019-06-30
US20190263879A1 (en)2019-08-29
DK3532486T3 (en)2021-10-18
US20190345214A1 (en)2019-11-14
CN109890410A (en)2019-06-14
CR20190208A (en)2019-05-27
WO2018081370A1 (en)2018-05-03
ES2897480T3 (en)2022-03-01
JOP20190096A1 (en)2019-04-28
IL266204B1 (en)2024-09-01
UY37457A (en)2018-04-30
DOP2019000107A (en)2019-09-30
IL314808A (en)2024-10-01
MX2019004955A (en)2019-06-24
MA46672A (en)2019-09-04
RS62677B1 (en)2021-12-31
CL2019001136A1 (en)2019-07-05
US11591379B2 (en)2023-02-28
KR20230129194A (en)2023-09-06
KR20240046290A (en)2024-04-08
US10858413B2 (en)2020-12-08
CN110099692B (en)2024-03-12
JOP20190096B1 (en)2023-09-17
PH12019500723A1 (en)2019-11-11
AU2025201677A1 (en)2025-03-27
KR20190072616A (en)2019-06-25
MY199666A (en)2023-11-15
US10428134B2 (en)2019-10-01
EP3534928A1 (en)2019-09-11
ZA202200648B (en)2024-02-28
IL266206B2 (en)2025-01-01
IL314935A (en)2024-10-01
AU2017348175A1 (en)2019-04-18
PE20190916A1 (en)2019-06-26
AU2017348180A1 (en)2019-04-18
IL266204B2 (en)2025-01-01
MX2019004952A (en)2019-06-24
US20240018208A1 (en)2024-01-18
KR102653376B1 (en)2024-04-02
NI201900043A (en)2019-10-25
JP2019534283A (en)2019-11-28
CN110036022A (en)2019-07-19
PH12019500749A1 (en)2019-11-11
US10968264B2 (en)2021-04-06
US20200385439A1 (en)2020-12-10
AU2022200089A1 (en)2022-02-03
US20250026803A1 (en)2025-01-23
SA519401647B1 (en)2022-01-26
IL301843A (en)2023-06-01
JP2022137031A (en)2022-09-21
US10640544B2 (en)2020-05-05
EP3988123C0 (en)2025-02-26
LT3532486T (en)2021-11-10
MX2019004954A (en)2019-06-24
HRP20211626T1 (en)2022-02-04
TW201827081A (en)2018-08-01
IL266202B2 (en)2023-09-01
EP3532486A4 (en)2020-06-24
DOP2019000178A (en)2020-02-16
TWI773699B (en)2022-08-11
ECSP19029835A (en)2019-05-31
EP3532092A1 (en)2019-09-04
SI3532486T1 (en)2021-12-31
CY1124732T1 (en)2022-07-22
SG11201902873RA (en)2019-05-30
IL266202A (en)2019-06-30
CO2019004203A2 (en)2019-05-10
MA46665B1 (en)2021-09-30
US10968265B2 (en)2021-04-06
PE20190917A1 (en)2019-06-26
HUE056442T2 (en)2022-02-28
DOP2019000106A (en)2019-09-30
CL2019001110A1 (en)2019-07-05
AU2017348175B2 (en)2021-08-26
EP3532092A4 (en)2020-07-01
AU2017348172B2 (en)2021-10-07
US20210206822A1 (en)2021-07-08
IL266204A (en)2019-06-30
TWI794189B (en)2023-03-01
US20200283491A1 (en)2020-09-10
US10961293B2 (en)2021-03-30
US20190367577A1 (en)2019-12-05
JOP20190097A1 (en)2019-04-28
PL3532486T3 (en)2022-01-31
AU2022200089B2 (en)2023-11-16
US20180127476A1 (en)2018-05-10
SA519401646B1 (en)2021-12-26
KR20190072615A (en)2019-06-25
US20190298849A1 (en)2019-10-03
US11401315B2 (en)2022-08-02
EP3988123B1 (en)2025-02-26
JP2023012467A (en)2023-01-25
TWI781118B (en)2022-10-21
US11767354B2 (en)2023-09-26
US20180117170A1 (en)2018-05-03
JP2024020405A (en)2024-02-14
PH12019500906A1 (en)2020-01-20
CL2019001129A1 (en)2019-07-05
IL266206B1 (en)2024-09-01
BR112019008351A2 (en)2019-10-01
TW202304972A (en)2023-02-01
US20210094998A1 (en)2021-04-01
JP7231539B2 (en)2023-03-01
MD3532486T2 (en)2022-01-31
EP3534928A4 (en)2020-08-12
EP3532486B1 (en)2021-09-22
NI201900044A (en)2019-09-09
JP2019534281A (en)2019-11-28
CA3041046A1 (en)2018-05-03
CR20190210A (en)2019-05-27
US12134636B2 (en)2024-11-05
BR112019008500A2 (en)2019-07-09
EP3988123A1 (en)2022-04-27
CA3041674A1 (en)2018-05-03
SG10202107777XA (en)2021-08-30
US20210163566A1 (en)2021-06-03
PE20191079A1 (en)2019-08-20
EP4574166A2 (en)2025-06-25
CN118085061A (en)2024-05-28
ECSP19029995A (en)2019-05-31
JOP20190095A1 (en)2019-04-28
CN110099692A (en)2019-08-06
MX2023014354A (en)2023-12-15
JP7387431B2 (en)2023-11-28
MX2023005465A (en)2023-05-22
CO2019003938A2 (en)2019-04-30
US10787495B2 (en)2020-09-29
UY37455A (en)2018-04-30
MA46718A (en)2019-09-11
SA519401642B1 (en)2022-03-07
SG11201902879SA (en)2019-05-30
KR20240046621A (en)2024-04-09
EP3532486B8 (en)2022-01-12
US20230365644A1 (en)2023-11-16
CO2019004186A2 (en)2019-05-10
CR20190209A (en)2019-08-21
EP3532486A1 (en)2019-09-04
IL266202B1 (en)2023-05-01
UY37456A (en)2018-04-30

Similar Documents

PublicationPublication DateTitle
SG11201902886SA (en)Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
SG11201908330PA (en)Farnesoid x receptor agonists and uses thereof
SG11201908650PA (en)Optimized antibody compositions for treatment of ocular disorders
SG11201907544VA (en)Jak inhibitors containing a 4-membered heterocyclic amide
SG11201804170RA (en)Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201900482SA (en)Compounds and compositions as inhibitors of endosomal toll-like receptors
SG11201906417RA (en)1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
SG11201907889YA (en)Glycan-interacting compounds and methods of use
SG11201906427QA (en)Heterocyclic spiro compounds as magl inhibitors
SG11201803726VA (en)Method for applying stable coating on silicone hydrogel contact lenses
SG11201809751XA (en)Egfr inhibitor compounds
SG11201906163TA (en)Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11201408173WA (en)Pyrimidinyl tyrosine kinase inhibitors
SG11201907604UA (en)Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201908512YA (en)Somatostatin modulators and uses thereof
SG11201803757UA (en)N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
SG11201811712QA (en)5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
SG11201900633XA (en)Piperidine cxcr7 receptor modulators
SG11201900558RA (en)Spiro-lactam nmda receptor modulators and uses thereof
SG11201908097YA (en)Pyrimidine derivatives as pge2 receptor modulators
SG11201804673WA (en)Novel anti-claudin antibodies and methods of use
SG11201908326YA (en)Methods of treating neurodegenerative diseases
SG11201901249YA (en)Aza-indazole compounds for use in tendon and/or ligament injuries
SG11201908729UA (en)Phenyl derivatives as pge2 receptor modulators
SG11201900551WA (en)Spiro-lactam nmda receptor modulators and uses thereof

[8]ページ先頭

©2009-2025 Movatter.jp